We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tetra Bio Pharma Inc | TSXV:TBP | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.215 | 0.21 | 0.215 | 0 | 01:00:00 |
ORLEANS, ON, Oct. 16, 2018 /CNW/ - October 17th, 2018 will be remembered as one of the most significant dates in Canadian history, in our lifetime.
While there will continue to be arguments on both sides of the debate, the Government of Canada has legislated that adults will have access to cannabis for recreational use, subject to a set of guidelines that will vary from province to province.
Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), is a Canadian company that is a global leader in the discovery and development of cannabis and cannabinoid-based pharmaceuticals and is the only company in North America to work with both Health Canada and the U.S. Food and Drug Administration on clinical programs to produce the rigorous scientific evidence required by these regulators as well as by medical professionals and insurance companies. If successful, the investigational trials will result in the manufacture of prescription drugs containing cannabis making these medications accessible to patients and reimbursed by private and public drug plans. These products will be produced for global markets including North America, Europe, South America and the Middle East. In addition to bio-pharma Tetra will introduce commercially available natural health products
While Tetra Bio-Pharma believes that cannabis has the potential to be of therapeutic benefit, as yet there is no scientific, safety, and efficacy data to support its usage. It is for this reason that we are pursuing a pharmaceutical pathway that is compliant with regulators, to establish the necessary clinical evidence that forms the basis of drug approvals. Health Canada, the United States Food and Drug Administration, and the European Medical Authority will only approve drugs for sale in these markets once they have successfully gone through a formal drug review process. This process, which can take anywhere between 6 months and two years, is how a drug application is reviewed by scientists in the Health Products and Food Branch (HPFB) of Health Canada as well by other international regulating bodies and as required, outside experts, to assess the safety, efficacy and quality of a drug.1 Throughout the process the well-being of patients is of paramount concern. Tetra Bio-Pharma is currently funding five Health Canada authorized clinical trials, including investigational trials for advanced cancer pain, a head to head trial comparing cannabis to fentanyl in breakthrough cancer pain, fibromyalgia, and chronic pain.
According to Dr. Guy Chamberland, Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, "the millions of individuals who currently suffer from painful conditions like cancer pain and fibromyalgia, or other medical problems like insomnia, depression, anxiety may be opening themselves up to unnecessary health risks with the use of recreational cannabis. Our concern also extends to seniors, children and even pets, among the most vulnerable in our society where it may be believed that cannabis will relieve common aches and pains."
At this point in time, and as Canadians decide how to navigate the new frontier of widespread access to recreational cannabis, Tetra Bio-Pharma would like to remind all Canadians that cannabis is a drug.
_________________________ |
1 https://spharm-inc.com/the-drug-approval-process-in-canada-an-eguide/ |
SOURCE Tetra Bio-Pharma
Copyright 2018 Canada NewsWire
1 Year Tetra Bio Pharma Chart |
1 Month Tetra Bio Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions